Synthetic analog · 4 amino acids · 461.5 Da

Livagen (KEDA) studies and research data

PepBank has 13 Livagen studies with results. 11 of them gave Livagen, with 27 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 27 results and 19 papers. Newer studies from Europe PMC

Results in people

0% of 27 results

Results in animals

7% of 27 results

Results in lab cells

93% of 27 results

From computer models

0% of 27 results

The molecule

Livagen identity

Identifiers, parent molecule, targets and development stage, from curated data.

Livagen is a synthetic 4-residue peptide in the Khavinson bioregulator family. Its sequence is Lys-Glu-Asp-Ala. Chemical identity does not establish a clinical benefit or a safe human dose.

Kind: Synthetic analog · 4 residues
Identifiers: PubChem CID87919683 (opens in a new tab)CAS433257-50-2
Development: No known clinical developmentNo clinical development phase was established from the identity and regulatory sources. Study titles do not establish a clinical phase.

Targets

No molecular target is recorded for this peptide.

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

4 amino acids

H-

KEDA

-OH

Properties

From identity sources

Formula: C₁₈H₃₁N₅O₉
Molecular weight: 461.5 g/mol
Monoisotopic mass: 461.2122 Da

PubChem CID 87919683(opens in a new tab)retrieved 2026-10-21

Calculated from the sequence

pKa set

Average mass: 461.47 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 461.2122 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 4.18; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: −1.06; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −2.275; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Instability index: 55.65; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 25.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 4.82 kcal/mol; Mean solubility value (negated) · Boman 2003; Above 2.48: high protein-binding potential (Boman).
Hydrophobic moment (μH): Not calculated; The sequence is too short for this method.
pI with each pKa set: EMBOSS 4.18Bjellqvist (ExPASy) 4.37IPC peptide 4.12IPC protein 4.19

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 4.18 · Net charge at pH 7.4: −1.06

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	2.00
1	2.00
2	1.96
3	1.61
4	0.28
5	−0.78
6	−0.98
7	−1.02
8	−1.20
9	−1.73
10	−2.10
11	−2.61
12	−2.94
13	−2.99
14	−3.00

Composition

Hydrophobic25% (1)A
Positive25% (1)K
Negative50% (2)D E

4 residues. Each residue counts in one class; F and W count as aromatic.

A Ala1 · 25%

I Ile0 · 0%

L Leu0 · 0%

M Met0 · 0%

V Val0 · 0%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys1 · 25%

R Arg0 · 0%

D Asp1 · 25%

E Glu1 · 25%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr0 · 0%

C Cys0 · 0%

G Gly0 · 0%

P Pro0 · 0%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 87919683(opens in a new tab)

C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N

Results by area

Livagen results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

13 of 19 studies have results (68%), published 2001 to 2017. Top row: every study. Bottom row: studies with results about Livagen (KEDA), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies19 in all, 2001 to 2023

Studies with results13 in all, 2001 to 2017

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Livagen studies on receptors and cell signals

11 results · people 0 · animals 2 · lab 9

Top 5 of 11 results

In rats, oral Livagen reduced digestive enzyme activity in young animals after two weeks.Advances in gerontology = Uspekhi gerontologii, 2005
In lab tests with human serum, Livagen inhibited enzymes that break down enkephalin.Izvestiia Akademii nauk. Seriia biologicheskaia, 2003
In cells from older people, Livagen activated ribosomal genes.Bulletin of experimental biology and medicine, 2002
In cells from older people, Livagen showed corrective activity in the adaptive-response experiment.Georgian medical news, 2007
In rats, Livagen increased digestive enzyme activity in old animals toward young control levels in most cases.Advances in gerontology = Uspekhi gerontologii, 2005

Livagen studies on cells, genes and aging

10 results · people 0 · animals 0 · lab 10

Top 5 of 10 results

In cells from old donors, Livagen induced chromosome 1 pericentromeric structural chromatin decondensation.Bulletin of experimental biology and medicine, 2004
In lab tests with atherosclerosis lymphocytes, Livagen alone normalized chromosome aberration indicators in both age groups.Georgian medical news, 2014
In lab tests with aged donor cells, Livagen could reactivate chromatin through deheterochromatinization.Annals of the New York Academy of Sciences, 2007
In lab tests with rat tissues, Livagen stimulated liver explant growth.Bulletin of experimental biology and medicine, 2001
In cells from old donors, Livagen induced pericentromeric heterochromatin decondensation in chromosome 1.Georgian medical news, 2006

Livagen studies on liver

4 results · people 0 · animals 0 · lab 4

Top 3 of 4 results

In lab tests, Livagen stimulated structural and functional stability in liver cell populations.Advances in gerontology = Uspekhi gerontologii, 2002
In lab tests, Livagen helped preserve liver cell structure.Advances in gerontology = Uspekhi gerontologii, 2002
In lab tests, Livagen increased cellular regeneration in liver culture.Advances in gerontology = Uspekhi gerontologii, 2002

Livagen studies on metabolism and nutrition

2 results · people 0 · animals 0 · lab 2

2 results

In cells from rats of different ages, Livagen increased protein synthesis, with the greatest effect in old animals' cells.Izvestiia Akademii nauk. Seriia biologicheskaia, 2001
In cells from old rats, Livagen increased the amplitude of protein synthesis fluctuations.Izvestiia Akademii nauk. Seriia biologicheskaia, 2001

Trials and papers

Livagen trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

19 studies match. Retracted studies are left out.

Showing 14 of 19 studiesquery qry_741f7a6f87310834e91e8a16

Studies with results

13 studies

Ex vivo tissue · rat · 2001

4 results

Tissue-specific effects of peptides.

Khavinson et al. 2001Bulletin of experimental biology and medicinecited by 3

PMID 11713572DOI 10.1023/a:1013058701974PUB-11713572

Full text at the publisher1 result where Livagen (KEDA) was given

Publisher page See results (4)

In vitro (cells) · 2002

3 results

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

VKh et al. 2002Bulletin of experimental biology and medicinecited by 3

PMID 12533768DOI 10.1023/a:1021924702103PUB-12533768

Full text at the publisher3 results where Livagen (KEDA) was given

Publisher page See results (3)

In vitro (cells) · 2004

8 results

Effects of short peptides on lymphocyte chromatin in senile subjects.

VKh et al. 2004Bulletin of experimental biology and medicinecited by 2

PMID 15085253DOI 10.1023/b:bebm.0000024393.40560.05PUB-15085253

Full text at the publisher2 results where Livagen (KEDA) was given

Publisher page See results (8)

In vitro (cells) · 2007

3 results

Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.

Lezhava et al. 2007Annals of the New York Academy of Sciencescited by 2

PMID 17460203DOI 10.1196/annals.1395.043PUB-17460203

Full text at the publisher2 results where Livagen (KEDA) was given (plus 1 on tools or combinations, listed separately)

Publisher page See results (3)

In vitro (cell-free) · 2003

6 results

[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].

Kost et al. 2003Izvestiia Akademii nauk. Seriia biologicheskaiacited by 1

PMID 12942748PUB-12942748

Full text at the publisher4 results where Livagen (KEDA) was given

Publisher page See results (6)

In vitro (cells) · rat · 2001

3 results

[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].

VIa et al. 2001Izvestiia Akademii nauk. Seriia biologicheskaiacited by 1

PMID 15926314DOI 10.1023/a:1016797124500PUB-15926314

Full text at the publisher2 results where Livagen (KEDA) was given

Publisher page See results (3)

Animal study (in vivo) · rat · 2005

5 results

[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].

Timofeeva et al. 2005Advances in gerontology = Uspekhi gerontologiicited by 1

PMID 16075683PUB-16075683

Full text at the publisher3 results where Livagen (KEDA) was given (plus 2 on tools or combinations, listed separately)

Publisher page See results (5)

In vitro (cells) · 2006

7 results

Anti-aging peptide bioregulators induce reactivation of chromatin.

Lezhava et al. 2006Georgian medical newscited by 1

PMID 16705247PUB-16705247

Full text at the publisher2 results where Livagen (KEDA) was given

Publisher page See results (7)

In vitro (cells) · 2007

1 result

[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].

Dzhokhadze et al. 2007Georgian medical newscited by 1

PMID 17921545PUB-17921545

Full text at the publisher1 result where Livagen (KEDA) was given

Publisher page See results (1)

Ex vivo tissue · 2002

4 results

[Functional morphology of an organotypic liver culture exposed to the peptide livagen].

IIu et al. 2002Advances in gerontology = Uspekhi gerontologii

PMID 12577697PUB-12577697

Full text at the publisher4 results where Livagen (KEDA) was given

Publisher page See results (4)

Not a test of Livagen (KEDA) alone · 2014

2 results

[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].

Georgian medical news

PMID 25341254PUB-25341254

Full text at the publisher2 results where Livagen (KEDA) was a tool, carrier or part of a combination

Publisher page See results (2)

In vitro (cells) · 2014

6 results

[Genomic instability in atherosclerosis].

Dzhokhadze et al. 2014Georgian medical news

PMID 25541832PUB-25541832

Full text at the publisher3 results where Livagen (KEDA) was given (plus 3 on tools or combinations, listed separately)

Publisher page See results (6)

Not a test of Livagen (KEDA) alone · 2017

4 results

[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].

Jokhadze et al. 2017Georgian medical news

PMID 28574395PUB-28574395

Full text at the publisher4 results where Livagen (KEDA) was a tool, carrier or part of a combination

Publisher page See results (4)

More studies

1 study

PubMed tag: none · 2020

[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]

Kuznik et al. 2020Advances in gerontology = Uspekhi gerontologiicited by 1

PMID 32362099PUB-32362099

Full text at the publisher

Publisher page

No result for Livagen (KEDA) (5 studies on this page)

These studies name Livagen (KEDA) but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Comparative Study · 2002

1 result

[Tissue-specific action of peptides in tissue culture of rats of various ages].

VKh et al. 2002Advances in gerontology = Uspekhi gerontologiicited by 1

PMID 12096446PUB-12096446

Full text at the publisher1 result

Publisher page See results (1)

PubMed tag: none · 2013

1 result

[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].

Dzhokhadze et al. 2013Georgian medical newscited by 1

PMID 24423684PUB-24423684

Full text at the publisher1 result

Publisher page See results (1)

PubMed tag: none · 2023

3 results

EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.

Lezhava et al. 2023Georgian medical newscited by 1

PMID 37042594PUB-37042594

Full text at the publisher3 results

Publisher page See results (3)

PubMed tag: none · 2008

2 results

[The effect of heavy metal ions and peptide bioregulators on the expression of chromosome fragile sites in the individuals of different age groups and breast cancer patients].

Dzhokhadze et al. 2008Georgian medical news

PMID 18830022PUB-18830022

Full text at the publisher2 results

Publisher page See results (2)

PubMed tag: none · 2020

5 results

EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON "AGED" HETEROCHROMATIN.

Lezhava et al. 2020Georgian medical news

PMID 33526740PUB-33526740

Full text at the publisher5 results

Publisher page See results (5)

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Livagen (KEDA) studies: 13 papers with results

Page 1 of 1

[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].
Timofeeva NM · Advances in gerontology = Uspekhi gerontologii · 2005
Animal study (in vivo) · rat · 5 results
Tissue-specific effects of peptides.
Khavinson VK · Bulletin of experimental biology and medicine · 2001
Ex vivo tissue · rat · 4 results
[Functional morphology of an organotypic liver culture exposed to the peptide livagen].
Riadnova IIu · Advances in gerontology = Uspekhi gerontologii · 2002
Ex vivo tissue · 4 results
Effects of Livagen peptide on chromatin activation in lymphocytes from old people.
Khavinson VKh · Bulletin of experimental biology and medicine · 2002
In vitro (cells) · 3 results
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.
Lezhava T · Annals of the New York Academy of Sciences · 2007
In vitro (cells) · 3 results
Effects of short peptides on lymphocyte chromatin in senile subjects.
Khavinson VKh · Bulletin of experimental biology and medicine · 2004
In vitro (cells) · 8 results
[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].
Dzhokhadze TA · Georgian medical news · 2007
In vitro (cells) · 1 result
Anti-aging peptide bioregulators induce reactivation of chromatin.
Lezhava T · Georgian medical news · 2006
In vitro (cells) · 7 results
[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].
Brodskiĭ VIa · Izvestiia Akademii nauk. Seriia biologicheskaia · 2001
In vitro (cells) · rat · 3 results
[Genomic instability in atherosclerosis].
Dzhokhadze TA · Georgian medical news · 2014
In vitro (cells) · 6 results
[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].
Kost NV · Izvestiia Akademii nauk. Seriia biologicheskaia · 2003
In vitro (cell-free) · 6 results
[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].
Jokhadze T · Georgian medical news · 2017
Not a test of Livagen (KEDA) alone · 4 results
[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].
Georgian medical news · 2014
Not a test of Livagen (KEDA) alone · 2 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The cited Drugs@FDA query returned no matching brand or active ingredient for Livagen or Lys-Glu-Asp-Ala. It did not search other spelling variants. This limited result does not establish complete FDA approval status. Compounding status remains unresolved.	21 Oct 2026	api.fda.gov (opens in a new tab)
EU	EMA	The EMA central data contained 2,754 records. No Livagen or Lys-Glu-Asp-Ala match appeared. This check does not establish EU national authorisations.	21 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Status unknown The peptide is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)
Russia	Note	Human medicine registration was not established. The Russian medicine register was accessible, but a complete name and formulation search remains unresolved.	21 Oct 2026	grls.rosminzdrav.ru (opens in a new tab)

Safety outcomes

Reported effects from study results.

No safety results from studies in people

The studies with results report no safety outcomes for this peptide. That does not mean it is safe.

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000095
Peptide version: 4
Peptide hash: edc158f45c464217…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256719
22 Oct 2026UpdatedData version 254542
21 Oct 2026UpdatedData version 228024
21 Oct 2026CreatedData version 226693

For developers

curl -s https://pepbank.io/v1/briefs/livagen

Evidence summary for Livagen (KEDA): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Receptor activity and mechanismWhole body	No results	Animal: 2 results from 1 study: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	Lab: 9 results from 4 studies: 6 increase, 2 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	11
Genome stabilityCardiovascular	No results	No results	Lab: 5 results from 2 studies: 1 increase, 4 decrease. Strongest design: In vitro (cells)	No results	5
Aging markersAging and longevity	No results	No results	Lab: 4 results from 2 studies: 3 increase, 1 not reported. Strongest design: In vitro (cells)	No results	4
Liver fat and liver functionLiver	No results	No results	Lab: 4 results from 1 study: 4 increase. Strongest design: Ex vivo tissue	No results	4
Protein and amino acid metabolismLiver	No results	No results	Lab: 2 results from 1 study: 2 increase. Strongest design: In vitro (cells)	No results	2
Cell proliferation and differentiationLiver	No results	No results	Lab: 1 result from 1 study: 1 increase. Strongest design: Ex vivo tissue	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Receptor activity and mechanismWhole body	No results	Animal: 2 results from 1 study: 1 increase, 1 decrease. Strongest design: Animal study (in vivo)	Lab: 9 results from 4 studies: 6 increase, 2 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	11
Genome stabilityCardiovascular	No results	No results	Lab: 5 results from 2 studies: 1 increase, 4 decrease. Strongest design: In vitro (cells)	No results	5
Aging markersAging and longevity	No results	No results	Lab: 4 results from 2 studies: 3 increase, 1 not reported. Strongest design: In vitro (cells)	No results	4
Liver fat and liver functionLiver	No results	No results	Lab: 4 results from 1 study: 4 increase. Strongest design: Ex vivo tissue	No results	4
Protein and amino acid metabolismLiver	No results	No results	Lab: 2 results from 1 study: 2 increase. Strongest design: In vitro (cells)	No results	2
Cell proliferation and differentiationLiver	No results	No results	Lab: 1 result from 1 study: 1 increase. Strongest design: Ex vivo tissue	No results	1

Livagen (KEDA) studies and research data

Livagen identity

Targets

Sequence and structure

Sequence

Properties

Net charge by pH

Composition

3D structure

2D structure

Livagen results by year and outcome

What the studies measured

Livagen studies on receptors and cell signals

Livagen studies on cells, genes and aging

Livagen studies on liver

Livagen studies on metabolism and nutrition

Livagen trials

Papers

Studies with results

Tissue-specific effects of peptides.

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

Effects of short peptides on lymphocyte chromatin in senile subjects.

Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.

[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].

[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].

[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].

Anti-aging peptide bioregulators induce reactivation of chromatin.

[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].

[Functional morphology of an organotypic liver culture exposed to the peptide livagen].

[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].

[Genomic instability in atherosclerosis].

[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].

More studies

[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]

[Tissue-specific action of peptides in tissue culture of rats of various ages].

[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].

EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.

[The effect of heavy metal ions and peptide bioregulators on the expression of chromosome fragile sites in the individuals of different age groups and breast cancer patients].

EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON "AGED" HETEROCHROMATIN.

Newer studies

Livagen (KEDA) studies: 13 papers with results

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

Livagen results by year and outcome

Livagen studies on receptors and cell signals

Livagen studies on cells, genes and aging

Livagen studies on liver

Livagen studies on metabolism and nutrition

Livagen trials

Papers

Studies with results

Tissue-specific effects of peptides.

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

Effects of short peptides on lymphocyte chromatin in senile subjects.

Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.

[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].

[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].

[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].

Anti-aging peptide bioregulators induce reactivation of chromatin.

[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].

[Functional morphology of an organotypic liver culture exposed to the peptide livagen].

[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].

[Genomic instability in atherosclerosis].

[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].

More studies

[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]

[Tissue-specific action of peptides in tissue culture of rats of various ages].

[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].

EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.

[The effect of heavy metal ions and peptide bioregulators on the expression of chromosome fragile sites in the individuals of different age groups and breast cancer patients].

EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON "AGED" HETEROCHROMATIN.

Livagen (KEDA) studies: 13 papers with results

Regulatory and safety

Doses studied

Data and API